FDA to introduce Wholesale Distributor Verification Requirements
Recommendation

7/8 October 2026
GDP in Practice – Core Requirements for Beginners
The US Food and Drug Administration FDA has published a Compliance Policy Guidance for Industry "Wholesale Distributor Verification Requirement for Saleable Returned Drug Product".
This Guidance is part of FDA's Drug Supply Chain Security Act (DSCSA) and will require wholesale distributors to verify a product identifier prior to further distributing returned product. To address concerns expressed by stakeholders and to minimize possible disruptions in the pharmaceutical distribution supply chain, FDA does not intend to take action against wholesale distributors who do not, prior to November 27, 2020, verify a product identifier prior to further distributing returned product as required under the DSCSA. This represents a 1-year delay in enforcement of this DSCSA requirement.
Related GMP News
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September
10.09.2026GDP in the US: FDA Launches DSCSA Assessment for Small Dispensers and Issues Exemptions
11.08.2026GDP for APIs: APIC Publishes Updated "How to Do" Document
11.08.2026Where to Find Information on UK Wholesale Authorisations
11.08.2026Call for Presentations: GDP Forum 2027 in Berlin
11.08.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 5


